Belluscura has developed the X-PLOR, a lightweight, portable oxygen delivery device aimed at treating the millions of people globally suffering from chronic lung diseases. The company plans to launch this novel and cost-effective device in the US in 2019, with Europe to follow.
Financial data drawn from last filed accounts don't necessarily reflect current trading activity. Financials provided by Company Check.
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Turnover | £32.73k | £285.92k | £186.25k | £90.98k | £0 |
Cash | £973.17k | £146.52k | £403.71k | £730.6k | £367.64k |
Increase in Cash | £1.8m | £-867.48k | £274.36k | £331.94k | £-376.28k |
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Audit Fees | £15.69k | £16.47k | £26.33k | £26.27k | £26.23k |
Cost of Sales | £25.33k | £296.74k | £191.8k | £80.86k | £0 |
Depreciation | £5.01k | £5.05k | £7.22k | £75.96k | £75.35k |
Directors Emoluments | £188.15k | £448.82k | £295.58k | £257.32k | £285.83k |
Dividends | - | - | - | - | - |
Export | - | - | - | - | £0 |
Gross Profit | £7.4k | £-10.82k | £-5.55k | £10.12k | £0 |
Interest Payments | £0 | £0 | £0 | £26.3k | £23.3k |
Operating Profit | £-743.1k | £-2.24m | £-1.12m | £-1.07m | £-1.38m |
Pretax Profit | £-743.1k | £-2.24m | £-1.12m | £-1.1m | £-1.4m |
Profit after Tax | £-743.1k | £-2.24m | £-1.12m | £-1.1m | £-1.4m |
Retained Profit | £-743.1k | £-2.24m | £-1.12m | £-1.1m | £-1.4m |
Taxation | £0 | £0 | £0 | £0 | £0 |
Turnover | £32.73k | £285.92k | £186.25k | £90.98k | £0 |
Wages & Salaries | £307.73k | £766.76k | £588.76k | £571.56k | £722.94k |
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Intangible Assets | £136.21k | £126.59k | £1.38m | £2.07m | £2.92m |
Bank Loans & Overdrafts | £0 | £0 | £0 | £0 | £0 |
Cash | £973.17k | £146.52k | £403.71k | £730.6k | £367.64k |
Miscellaneous Current Assets | £0 | £0 | £0 | £0 | £0 |
Miscellaneous Current Liabilities | £45.85k | £260.44k | £78.32k | £190.36k | £51.95k |
Other Debtors | £66.57k | £56.12k | £10.66k | £0 | £121.26k |
Other Long Term Finance | £0 | £0 | £0 | £294.3k | £229.86k |
Other Short Term Finance | £137k | £169.33k | £0 | £58.02k | £110.73k |
Stock | £3.43k | £62.76k | £97.16k | £0 | £0 |
Tangible Accounts | £35.25k | £1.04m | £22.16k | £350.81k | £275.46k |
Total Current Assets | £1.06m | £326.04k | £535.84k | £776.25k | £507.37k |
Total Current Liabilities | £313.9k | £1.08m | £191.71k | £272.39k | £162.69k |
Total Fixed Assets | £171.46k | £1.17m | £1.4m | £2.43m | £3.19m |
Total Long Term Finance | £0 | £0 | £0 | £294.3k | £238.97k |
Trade Creditors | £131.05k | £646.88k | £113.39k | £24.01k | £0 |
Trade Debtors | £12.38k | £60.62k | £24.31k | £3.99k | £0 |
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Profit & Loss Account Reserve | £-743.1k | £141.99k | £-985.15k | £-2.01m | £1.9m |
Called up share capital | £91.6k | £127.44k | £345.95k | £458.29k | £581.93k |
Revaluation Reserve | £0 | £0 | £0 | £0 | £0 |
Shareholder Funds | £913.11k | £420.6k | £1.74m | £2.64m | £3.3m |
Sundry Reserves | £1.56m | £151.18k | £2.38m | £116.64k | £116.64k |
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Increase in Cash | £1.8m | £-867.48k | £274.36k | £331.94k | £-376.28k |
Net Cash Flow Before Financing | £-15.83k | £722.36k | £-2.42m | £-1.47m | £-1.88m |
Net Cash Flow From Financing | £1.81m | £-1.59m | £2.69m | £1.8m | £1.51m |
Net Cash Flow From Operations | £-545.75k | £-1.41m | £-1.81m | £-708.59k | £-1.04m |
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Net Assets | £913.11k | £420.6k | £1.74m | £2.64m | £3.3m |
Net Worth | £776.9k | £294.01k | £366.29k | £560.37k | £381.17k |
Total Assets | £1.23m | £1.5m | £1.93m | £3.2m | £3.7m |
Total Liabilities | £313.9k | £1.08m | £191.71k | £566.7k | £401.66k |
Working Capital | £741.65k | £-750.61k | £344.13k | £503.86k | £344.68k |
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Creditor Days | 1.46k% | 902.73% | 221.6% | 96.07% | 0% |
Current Debt Ratio | 0.34% | 2.55% | 0.1% | 0.1% | 0.04% |
Current Ratio | 3.36% | 0.3% | 2.8% | 2.85% | 3.12% |
Debtor Days | 137.74% | 84.6% | 47.51% | 15.97% | 0% |
Equity In Percentage | 83.7% | 30.7% | 312.4% | 233.8% | 421.6% |
Gearing | 0% | 0% | 0% | 11.2% | 7.2% |
Liquidity Ratio Or Acid Test | 3.35% | 0.24% | 2.28% | 2.84% | 3.11% |
Pre Tax Profit Margin | -2.27k% | -783.34% | -601.98% | -1.21k% | 0% |
Return On Capital Employed | -81.38% | -532.49% | -64.32% | -37.44% | -39.5% |
Return On Net Assets Employed | -81.38% | -532.49% | -64.32% | -41.63% | -42.36% |
Return On Total Assets Employed | -60.56% | -149.58% | -57.95% | -34.26% | -37.77% |
Sales Or Net Working Capital | 0% | 0% | 0% | 0% | 0% |
Stock Turnover Ratio | 10.46% | 21.95% | 52.16% | 0% | 0% |
Total Debt Ratio | 0.34% | 2.55% | 0.1% | 0.21% | 0.12% |